A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma

Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

(2014) Hien K. Duong et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

How we manage autologous stem cell transplantation for patients with multiple myeloma

(2014) M. A. Gertz et al.   BLOOD

Advances in stem cell mobilization

(2014) Rusudan K. Hopman et al.   BLOOD REVIEWS

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

(2014) M Mohty et al.   BONE MARROW TRANSPLANTATION

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation and is effective even in heavily pretreated patients

(2014) R E Clark et al.   Blood Cancer Journal

Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

(2013) Sergio Giralt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization

(2013) R. Niesvizky et al.   CLINICAL CANCER RESEARCH

Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies

(2012) Dawn Sheppard et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure

(2012) L J Costa et al.   BONE MARROW TRANSPLANTATION

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

(2012) Raija Silvennoinen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization

(2012) S Li et al.   LEUKEMIA

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

(2011) F Cavallo et al.   LEUKEMIA

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial

(2010) P Moreau et al.   LEUKEMIA

Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma

(2009) Uday Popat et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

How I treat multiple myeloma in younger patients

(2009) A. K. Stewart et al.   BLOOD

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

(2009) R. Pal et al.   BLOOD

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma

(2008) Tomer Mark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

(2008) H Paripati et al.   LEUKEMIA